Glenmark - Medicamenta Pharma company (Високе-Мито)
Czech Republic /
Pardubicky /
Vysoke Myto /
Високе-Мито
World
/ Czech Republic
/ Pardubicky
/ Vysoke Myto
World / Czech Republic / Pardubický
company, production
Glenmark Holdings SA (GHSA), a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd, will acquire a majority shareholding (ie over 90 per cent) of the Czech pharmaceutical Medicamenta A.S, for an undisclosed sum.
Under Czech Law, a holding of more than 90 per cent shares in a company triggers a mandatory takeover bid for the remaining shares.
This acquisition provides Glenmark with strategic entry point into two of the fastest growing and attractive markets in Europe - the Czech Republic and Slovakia.
The pharmaceutical market in the both countries is dominated by branded generics and the Company expects Medicamenta to provide a base for its branded business in Europe, and will also look to develop and expand Medicamenta's current portfolio of pharmaceutical products.
Medicamenta's leading products, Ataraigin, is a household brand in Czech Republic and Slovakia - a product for the treatment of headache, cold and pain.
Medicamenta's projects revenues for the calendar year 2007 are $8 million. Medicamenta has 60 employees and brings along a basket of 29 solid dose and semi-solid products. These products are manufactured at its plant in Vysoke Myto in the Czech Republic spread over 13,000 sq metres.
Glenmark plans to make use of Medicamenta's plant capacity to support its broader operation, by providing additional manufacturing, packaging, quality release and warehousing for its European business.
Under Czech Law, a holding of more than 90 per cent shares in a company triggers a mandatory takeover bid for the remaining shares.
This acquisition provides Glenmark with strategic entry point into two of the fastest growing and attractive markets in Europe - the Czech Republic and Slovakia.
The pharmaceutical market in the both countries is dominated by branded generics and the Company expects Medicamenta to provide a base for its branded business in Europe, and will also look to develop and expand Medicamenta's current portfolio of pharmaceutical products.
Medicamenta's leading products, Ataraigin, is a household brand in Czech Republic and Slovakia - a product for the treatment of headache, cold and pain.
Medicamenta's projects revenues for the calendar year 2007 are $8 million. Medicamenta has 60 employees and brings along a basket of 29 solid dose and semi-solid products. These products are manufactured at its plant in Vysoke Myto in the Czech Republic spread over 13,000 sq metres.
Glenmark plans to make use of Medicamenta's plant capacity to support its broader operation, by providing additional manufacturing, packaging, quality release and warehousing for its European business.
Nearby cities:
Coordinates: 49°57'31"N 16°9'17"E
- Medin 44 km
- ČSAD Tišnov 71 km
- TÜV SÜD Czech s.r.o. 98 km
- TÜV SÜD Czech s.r.o. 101 km
- Ricardo Prague Technical Centre 123 km
- Alstom Praha Sales Office 124 km
- Tyco Fire & Intergrated Solutions s.r.o. 124 km
- Rigaku Innovative Technologies Europe s.r.o. 124 km
- Horizon Fuel Cell Technologies 125 km
- TÜV SÜD Czech s.r.o. Kancelář České Budějovice 164 km
- Iveco Czech Republic 0.6 km
- Sruby railway stop 3.7 km
- Dobrikov railway stop 4.3 km
- Zamrsk (Stara Bazantnice) 4.9 km
- Stodola 5.1 km
- Zamrsk railway station 5.2 km
- Sedlistka railway stop 7.3 km
- Plchuvky railway stop 9 km
- Uhersko railway station 11 km
- Cermna nad Orlici railway station 12 km